Castle Biosciences
CSTL • NASDAQ
Castle Biosciences is a medical - diagnostics & research company in the healthcare sector trading on NASDAQ, led by CEO Derek J. Maetzold, with a market cap of $945.7M.
CEODerek J. Maetzold
Market Cap$945.7M
Medical - Diagnostics & Research
Healthcare
Employees638.0
Websitecastlebiosciences.com
Country
United States of America
Next Earnings
Upcoming earnings announcement for Castle Biosciences
Date
Monday, May 4, 2026 (in 3 months)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.35
Revenue Estimate
$79.5M
Earnings History
Past 11 earnings reports for Castle Biosciences
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Nov 3, 2025 | Q3 2025 | -$0.02Est: -$0.44 | +95.5% | $83.0MEst: $71.2M | +16.6% |  10-Q |
| Aug 4, 2025 | Q2 2025 | $0.15Est: -$0.50 | +130.0% | $86.2MEst: $72.4M | +19.0% | 10-Q |
| May 5, 2025 | Q1 2025 | -$0.20Est: -$0.07 | -185.7% | $88.0MEst: $80.4M | +9.5% | 10-Q |
| Feb 27, 2025 | Q4 2024 | $0.32Est: $0.04 | +700.0% | $86.3MEst: $83.9M | +2.9% | 10-K |
| Nov 4, 2024 | Q3 2024 | $0.08Est: -$0.06 | +233.3% | $85.8MEst: $79.8M | +7.4% | 10-Q |
| Aug 5, 2024 | Q2 2024 | $0.31Est: -$0.29 | +206.9% | $87.0MEst: $69.1M | +25.9% | 10-Q |
| May 2, 2024 | Q1 2024 | -$0.09Est: -$0.33 | +72.7% | $73.0MEst: $66.2M | +10.2% | 10-Q |
| Feb 28, 2024 | Q4 2023 | -$0.10Est: -$0.54 | +81.5% | $66.1MEst: $56.3M | +17.5% | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.26Est: -$0.76 | +65.8% | $61.5MEst: $48.5M | +26.7% | — |
| Aug 2, 2023 | Q2 2023 | -$0.70Est: -$1.01 | +30.7% | $50.1MEst: $43.5M | +15.2% | 10-Q |
| May 3, 2023 | Q1 2023 | -$1.10Est: -$0.89 | -23.6% | $42.0MEst: $37.4M | +12.5% | 10-Q |